iRadimed (NASDAQ:IRMD) CEO Sells $219,700.00 in Stock

20 May 2026, 17:13 by Jessica Moore · The Cerbat Gem

iRadimed Corporation (NASDAQ:IRMD – Get Free Report) CEO Roger Susi sold 2,500 shares of the stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $87.88, for a total value of $219,700.00. Following the sale, the chief executive officer directly owned 2,172,500 shares of the company’s stock, valued at $190,919,300. The trade was a 0.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Trading Up 3.5%

Shares of IRMD traded up $3.04 on Wednesday, reaching $90.40. 169,288 shares of the company’s stock traded hands, compared to its average volume of 90,268. The stock has a market cap of $1.16 billion, a PE ratio of 49.40 and a beta of 0.90. The stock’s 50 day simple moving average is $93.22 and its two-hundred day simple moving average is $94.91. iRadimed Corporation has a 52-week low of $50.88 and a 52-week high of $107.90.

iRadimed (NASDAQ:IRMD – Get Free Report) last issued its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. The company had revenue of $21.98 million during the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Analysts forecast that iRadimed Corporation will post 1.52 earnings per share for the current year.

iRadimed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. iRadimed’s dividend payout ratio (DPR) is currently 43.72%.

Institutional Trading of iRadimed

Large investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its holdings in shares of iRadimed by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after acquiring an additional 33,072 shares during the period. Principal Financial Group Inc. bought a new position in shares of iRadimed in the third quarter worth $422,000. Tudor Investment Corp ET AL bought a new position in shares of iRadimed in the third quarter worth $666,000. Baader Bank Aktiengesellschaft bought a new position in shares of iRadimed in the fourth quarter worth $595,000. Finally, RFG Advisory LLC bought a new position in shares of iRadimed in the fourth quarter worth $1,594,000. 92.34% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. Weiss Ratings raised iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. Lake Street Capital reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital raised iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Roth Mkm reissued a “buy” rating and issued a $120.00 target price on shares of iRadimed in a research report on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $120.00.

Read Our Latest Analysis on iRadimed

iRadimed Company Profile

(Get Free Report)

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.